A detailed history of Baugh & Associates, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Baugh & Associates, LLC holds 43,970 shares of ABBV stock, worth $8.51 Million. This represents 4.12% of its overall portfolio holdings.

Number of Shares
43,970
Previous 46,206 4.84%
Holding current value
$8.51 Million
Previous $8.41 Million 10.38%
% of portfolio
4.12%
Previous 4.52%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024

SELL
$154.79 - $180.76 $346,110 - $404,179
-2,236 Reduced 4.84%
43,970 $7.54 Million
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $5,274 - $6,009
-33 Reduced 0.07%
46,206 $8.41 Million
Q4 2023

Jan 10, 2024

SELL
$137.6 - $154.97 $87,513 - $98,560
-636 Reduced 1.36%
46,239 $7.17 Million
Q3 2023

Oct 13, 2023

SELL
$133.59 - $154.65 $18,168 - $21,032
-136 Reduced 0.29%
46,875 $6.99 Million
Q2 2023

Jul 20, 2023

BUY
$132.51 - $164.9 $90,769 - $112,956
685 Added 1.48%
47,011 $6.33 Million
Q1 2023

Apr 27, 2023

SELL
$144.61 - $166.54 $139,693 - $160,877
-966 Reduced 2.04%
46,326 $7.38 Million
Q4 2022

Jan 27, 2023

SELL
$138.31 - $165.87 $1,659 - $1,990
-12 Reduced 0.03%
47,292 $0
Q3 2022

Oct 07, 2022

SELL
$134.21 - $153.93 $2,281 - $2,616
-17 Reduced 0.04%
47,304 $6.35 Million
Q2 2022

Jul 19, 2022

SELL
$137.62 - $174.96 $72,250 - $91,854
-525 Reduced 1.1%
47,321 $7.25 Million
Q1 2022

Apr 20, 2022

SELL
$131.98 - $163.75 $30,355 - $37,662
-230 Reduced 0.48%
47,846 $7.76 Million
Q4 2021

Jan 14, 2022

BUY
$107.43 - $135.93 $39,641 - $50,158
369 Added 0.77%
48,076 $6.51 Million
Q3 2021

Oct 13, 2021

SELL
$106.4 - $120.78 $425 - $483
-4 Reduced 0.01%
47,707 $5.15 Million
Q2 2021

Jul 12, 2021

SELL
$105.21 - $117.21 $60,600 - $67,512
-576 Reduced 1.19%
47,711 $5.37 Million
Q1 2021

Apr 16, 2021

BUY
$102.3 - $112.62 $16,265 - $17,906
159 Added 0.33%
48,287 $5.23 Million
Q4 2020

Jan 13, 2021

BUY
$80.49 - $108.67 $43,303 - $58,464
538 Added 1.13%
48,128 $5.16 Million
Q3 2020

Oct 28, 2020

SELL
$85.91 - $100.83 $70,875 - $83,184
-825 Reduced 1.7%
47,590 $4.17 Million
Q2 2020

Jul 09, 2020

BUY
$73.37 - $98.18 $71,609 - $95,823
976 Added 2.06%
48,415 $4.75 Million
Q1 2020

Apr 21, 2020

SELL
$64.5 - $97.79 $32,508 - $49,286
-504 Reduced 1.05%
47,439 $3.61 Million
Q4 2019

Jan 13, 2020

SELL
$72.13 - $90.25 $32,458 - $40,612
-450 Reduced 0.93%
47,943 $4.25 Million
Q3 2019

Oct 08, 2019

BUY
$62.98 - $75.72 $16,059 - $19,308
255 Added 0.53%
48,393 $3.66 Million
Q2 2019

Jul 23, 2019

BUY
$65.7 - $83.98 $450,570 - $575,934
6,858 Added 16.61%
48,138 $3.5 Million
Q1 2019

Apr 05, 2019

SELL
$77.14 - $90.79 $18,359 - $21,608
-238 Reduced 0.57%
41,280 $3.33 Million
Q4 2018

Jan 17, 2019

SELL
$77.85 - $96.01 $4,671 - $5,760
-60 Reduced 0.14%
41,518 $3.83 Million
Q3 2018

Nov 02, 2018

BUY
$88.91 - $98.84 $112,382 - $124,933
1,264 Added 3.14%
41,578 $3.93 Million
Q2 2018

Jul 27, 2018

SELL
$89.78 - $106.23 $146,431 - $173,261
-1,631 Reduced 3.89%
40,314 $3.74 Million
Q1 2018

Apr 25, 2018

SELL
$92.01 - $123.21 $32,663 - $43,739
-355 Reduced 0.84%
41,945 $3.97 Million
Q4 2017

Feb 08, 2018

BUY
$89.56 - $98.21 $3.79 Million - $4.15 Million
42,300
42,300 $4.09 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Baugh & Associates, LLC Portfolio

Follow Baugh & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baugh & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baugh & Associates, LLC with notifications on news.